Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.

ABSTRACT:

Background

Preoperative chemoradiotherapy (PCRT) followed by surgery and adjuvant chemotherapy is the current standard treatment for stage II/III rectal cancer. However, radiotherapy in the pelvic area is commonly associated with complications such as anastomotic leakage, sexual dysfunction, and fecal incontinence. Recently, the MERCURY study showed that preoperative high-resolution magnetic resonance imaging (MRI) helped to selectively avoid PCRT. It remains unclear whether PCRT is necessary in patients who can achieve a negative circumferential resection margin (CRM) with surgery alone and in patients with cT_1-2N₁ or cT₃N₀ without CRM involvement and lateral lymph node metastasis. This study aims to evaluate the efficacy of upfront radi

SUBMITTER: Lee JB 

PROVIDER: S-EPMC7140505 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature